Stichworte
Pulmonale Krankheiten (Fachgebiet) ×
Zeige mehr Stichworte
Inhaltsverzeichnis
  1. 1. Klinische Studie
  2. 2. Routinedokumentation
  3. 3. Register-/Kohortenstudien
  4. 4. Qualitätssicherung
  5. 5. Datenstandard
  6. 6. Patientenfragebogen
  7. 7. Medizinische Fachrichtung
Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

429 Suchergebnisse.

Screening - GSK Milveterol COPD 100527

- 18.06.17 - 1 Formular, 9 Itemgruppen, 132 Datenelemente, 1 Sprache
Itemgruppen: Inclusion/Exclusion criteria, Demography, Duration of Asthma, Vital Signs, 12-Lead Electrocardiogram, Pulmonary function, Hematology, Clinical Chemistry, Urinalysis
Study ID: 100527 Clinical Study ID: B2E100527 Study Title: A randomised, double blind, placebo controlled, parellel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 Sponsor: GlaxoSmithKline Phase: phase 2 Study Recruitment Status: Completed Generic Name: milveterol Trade Name: Milveterol Study Indication: Pulmonary Disease, Chronic Obstructive

Eligibility Carcinoma NCT02355431

- 16.02.19 - 1 Formular, 2 Itemgruppen, 14 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
INCB039110 in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations; ODM derived from: https://clinicaltrials.gov/show/NCT02355431

Eligibility SECONDARY PULMONARY HYPERTENSION NCT01270750

- 22.01.19 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Bosentan for Severe Mitral Valve Dysfunction; ODM derived from: https://clinicaltrials.gov/show/NCT01270750

Eligibility Pulmonary Hypertension NCT02345616

- 17.01.19 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Role of the Nitric Oxide (NO) in Pre-oxygenation Before Anesthetic Induction in Patients With a Pulmonary Hypertension in Cardiac Surgery. Pilot Study of Feasibility; ODM derived from: https://clinicaltrials.gov/show/NCT02345616

Eligibility Pulmonary Arterial Hypertension NCT01934582

- 17.01.19 - 1 Formular, 2 Itemgruppen, 8 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
A Pharmacokinetic Substudy of the TDE-PH-304 Protocol; ODM derived from: https://clinicaltrials.gov/show/NCT01934582

Eligibility Pulmonary Arterial Hypertension NCT01553721

- 17.01.19 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH); ODM derived from: https://clinicaltrials.gov/show/NCT01553721

Eligibility Pulmonary Arterial Hypertension NCT01468545

- 17.01.19 - 1 Formular, 2 Itemgruppen, 8 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System; ODM derived from: https://clinicaltrials.gov/show/NCT01468545

Eligibility NSCLC NCT02404675

- 09.01.19 - 1 Formular, 2 Itemgruppen, 8 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation; ODM derived from: https://clinicaltrials.gov/show/NCT02404675

Eligibility Non-Squamous Non-Small Cell Lung Cancer NCT01077713

- 09.01.19 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01077713

Eligibility Non-Squamous Non-Small Cell Lung Cancer NCT00883779

- 09.01.19 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00883779

Eligibility Non-Small-Cell Lung Carcinoma NCT01786122

- 09.01.19 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Clinical Trial: Effectiveness and Efficiency of Physical Exercise in Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01786122

Eligibility Non-small-cell Lung Cancer NCT01929200

- 09.01.19 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation; ODM derived from: https://clinicaltrials.gov/show/NCT01929200